Grand Pharmaceutical Group Limited (HKG:0512)
Hong Kong
· Delayed Price · Currency is HKD 6.33
+0.05 (0.80%)
Apr 3, 2025, 4:08 PM HKT
HKG:0512 Income Statement
Financials in millions HKD. Fiscal year is January - December.
Millions HKD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 11,645 | 10,530 | 9,562 | 8,598 | 6,353 | Upgrade
|
| Revenue Growth (YoY) | 10.59% | 10.12% | 11.22% | 35.34% | -3.61% | Upgrade
|
| Cost of Revenue | 4,907 | 4,006 | 3,611 | 3,351 | 2,318 | Upgrade
|
| Gross Profit | 6,738 | 6,524 | 5,951 | 5,247 | 4,035 | Upgrade
|
| Selling, General & Admin | 4,621 | 3,802 | 3,396 | 3,307 | 2,545 | Upgrade
|
| Other Operating Expenses | -176.83 | -195.17 | -170.42 | -242.12 | -293.48 | Upgrade
|
| Operating Expenses | 4,517 | 3,665 | 3,203 | 3,077 | 2,252 | Upgrade
|
| Operating Income | 2,221 | 2,860 | 2,748 | 2,170 | 1,783 | Upgrade
|
| Interest Expense | -180.24 | -205.15 | -137.49 | -92.96 | -115.42 | Upgrade
|
| Interest & Investment Income | 6.31 | 7.75 | 19.81 | 74.95 | 18.05 | Upgrade
|
| Earnings From Equity Investments | 148.72 | -25.01 | -43.79 | 113.86 | 61.98 | Upgrade
|
| Other Non Operating Income (Expenses) | -27.78 | -32.34 | 40.1 | -8.35 | - | Upgrade
|
| EBT Excluding Unusual Items | 2,168 | 2,605 | 2,627 | 2,258 | 1,748 | Upgrade
|
| Merger & Restructuring Charges | -1.3 | - | -0.22 | - | - | Upgrade
|
| Impairment of Goodwill | -49.07 | -39.14 | -36.44 | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 675.93 | 89.27 | -94.62 | 484.85 | 271.41 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | 2.37 | 8.58 | Upgrade
|
| Asset Writedown | 4.39 | 5.45 | 21.35 | 29.58 | 45.65 | Upgrade
|
| Other Unusual Items | 54.21 | -316.18 | - | 11.42 | - | Upgrade
|
| Pretax Income | 2,852 | 2,344 | 2,517 | 2,786 | 2,074 | Upgrade
|
| Income Tax Expense | 386.3 | 448.76 | 418.64 | 380.8 | 292.37 | Upgrade
|
| Earnings From Continuing Operations | 2,466 | 1,895 | 2,098 | 2,405 | 1,781 | Upgrade
|
| Minority Interest in Earnings | 2.32 | -15.44 | -18.83 | -2.47 | 11.45 | Upgrade
|
| Net Income | 2,468 | 1,880 | 2,079 | 2,403 | 1,793 | Upgrade
|
| Net Income to Common | 2,468 | 1,880 | 2,079 | 2,403 | 1,793 | Upgrade
|
| Net Income Growth | 31.30% | -9.59% | -13.45% | 34.02% | 55.75% | Upgrade
|
| Shares Outstanding (Basic) | 3,502 | 3,508 | 3,542 | 3,548 | 3,445 | Upgrade
|
| Shares Outstanding (Diluted) | 3,502 | 3,508 | 3,542 | 3,548 | 3,445 | Upgrade
|
| Shares Change (YoY) | -0.17% | -0.97% | -0.16% | 2.98% | 2.19% | Upgrade
|
| EPS (Basic) | 0.70 | 0.54 | 0.59 | 0.68 | 0.52 | Upgrade
|
| EPS (Diluted) | 0.70 | 0.54 | 0.59 | 0.68 | 0.52 | Upgrade
|
| EPS Growth | 31.52% | -8.70% | -13.31% | 30.14% | 51.15% | Upgrade
|
| Free Cash Flow | 1,342 | 1,937 | 1,216 | 1,534 | 1,247 | Upgrade
|
| Free Cash Flow Per Share | 0.38 | 0.55 | 0.34 | 0.43 | 0.36 | Upgrade
|
| Dividend Per Share | 0.260 | 0.260 | 0.140 | 0.110 | 0.110 | Upgrade
|
| Dividend Growth | - | 85.71% | 27.27% | - | 14.58% | Upgrade
|
| Gross Margin | 57.87% | 61.96% | 62.24% | 61.03% | 63.52% | Upgrade
|
| Operating Margin | 19.07% | 27.16% | 28.74% | 25.24% | 28.07% | Upgrade
|
| Profit Margin | 21.20% | 17.85% | 21.75% | 27.94% | 28.22% | Upgrade
|
| Free Cash Flow Margin | 11.53% | 18.40% | 12.72% | 17.84% | 19.63% | Upgrade
|
| EBITDA | 2,675 | 3,212 | 3,109 | 2,493 | 2,055 | Upgrade
|
| EBITDA Margin | 22.97% | 30.50% | 32.52% | 28.99% | 32.34% | Upgrade
|
| D&A For EBITDA | 453.38 | 352.36 | 361.05 | 322.53 | 271.48 | Upgrade
|
| EBIT | 2,221 | 2,860 | 2,748 | 2,170 | 1,783 | Upgrade
|
| EBIT Margin | 19.07% | 27.16% | 28.74% | 25.24% | 28.07% | Upgrade
|
| Effective Tax Rate | 13.54% | 19.14% | 16.63% | 13.67% | 14.10% | Upgrade
|
Updated Mar 18, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.